COGENT BIOSCIENCES INC - BEZUCLASTINIB TRIAL SHOWED 89% OF PATIENTS ACHIEVING ≥50% REDUCTION IN BONE MARROW MAST CELLS

Reuters · 2d ago

Please log in to view news